WELCOME TO The HEALTHCARE REPORT
Newsletter | Member Login | Signup
Home > Companies > Ministry of Health - UAE
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Webinar
DECK 7 | February 04, 2020
Being one of the best lead-gen service providers in San Diego, California, DECK 7 is more data-focused than ever. The brand has optimized its strategic marketing approach by scaling ABM in a number of effective ways. By combining its time-tested ABM framework with a strong data-driven approach, DECK 7 is empowering numerous brands in maximizing growth and driving actionable results. DECK 7’s ABM prowess is defined by its skilled team members and their advanced approach to B2B marketing. Th...
Business Wire | August 26, 2020
V2 Communications (V2), a public relations and digital communications agency for disruptive global brands, has added CarePort Health (CarePort), a market leader in care transitions software, to its client portfolio. CarePort joins companies such as DirectPath and Current Health on V2’s healthcare client roster. CarePort is the leading care coordination network with hospitals, post-acute providers, payers and physician groups connected across the U.S. The end-to-end platform bridges acute a...
HealtheMed | September 18, 2020
HealtheMed today announces the launch of its new telemedicine platform to bring healthcare into the homes of the most vulnerable Minnesota Medicaid populations. HealtheMed has closed a seed round of capital from angel investors to fuel the launch of its new service and expansion to markets across the United States. HealtheMed’s unique platform will enable Medicaid special needs populations to quickly access medica...
FUTURE OF HEALTHCARE
Medicago | May 06, 2022
Medicago announced the publication of the results from the Phase 3 study of COVIFENZ®, COVID-19 vaccine recombinant, adjuvanted, in the New England Journal of Medicine. The Phase 3 trial studied the two-dose regimen of COVIFENZ® given 21 days apart versus placebo in over 24,000 subjects aged 18 and above. Common side effects in the vaccine group included injection site pain, headache, fatigue, fever, muscle aches, and chills. COVIFENZ® is indicated for active immunizatio...
infographic
Video
HEALTH TECHNOLOGY
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE